TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and...
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of...
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.29 | 5.90631364562 | 4.91 | 5.2 | 4.9 | 1423 | 5.10122243 | CS |
4 | 0.1 | 1.96078431373 | 5.1 | 5.22 | 4.9 | 1260 | 5.04594989 | CS |
12 | -3.8 | -42.2222222222 | 9 | 9 | 4.66 | 1519 | 5.50201475 | CS |
26 | -3.2 | -38.0952380952 | 8.4 | 9 | 4.66 | 1549 | 5.63058947 | CS |
52 | -3.2 | -38.0952380952 | 8.4 | 9 | 4.66 | 1549 | 5.63058947 | CS |
156 | -3.2 | -38.0952380952 | 8.4 | 9 | 4.66 | 1549 | 5.63058947 | CS |
260 | -3.2 | -38.0952380952 | 8.4 | 9 | 4.66 | 1549 | 5.63058947 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.